Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying
Christos S. Karapetis(Clínica Alemana), Ian Olver(The University of Adelaide), Phil Parente(Eastern Health), Prunella Blinman(The University of Sydney), Bogda Koczwara(Flinders University), B. Stein(Centre for Cancer Biology), Michael Millward(The University of Western Australia), Rosemary Harrup(University of Tasmania), Linda Milleshkin(Peter MacCallum Cancer Centre), Ian Haines(Cabrini Hospital)
Cited by 27
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537